What's new in atopic eczema?

Abstract

Existing treatment modalities such as barrier repair therapy, topical immunosuppressive agents, antiseptic treatment as well as systemic treatment options are discussed. The review aims to summarize the most recent findings of more innovative treatment approaches such as modulation of cytokines or chemokines, modulation of T-cell responses or anti-IgE therapy.

Association Between Atopic Dermatitis and Autism Spectrum Disorders: A Systematic Review

“…It is usually referred to as 'atopic' even though it shows the typical atopic patterns of type I (immediate type) sensitization to environmental allergens in only a subset of individuals [14]. AD usually begins within the first year of life, preceding the other atopic diseases in 50 % of cases [15]. Children who have already experienced AD have an increased risk of developing one or more of the other atopic diseases, and for this reason AD is often considered as the beginning of the 'atopic march' [16,17].…”

Emollient Therapy and Skin Barrier Function

“…It may be possible to identify constituents which have an advantageous effect on the protease activity. This knowledge should allow the formulation of better emollients for the treatment of dry skin and atopic dermatitis, a problem that has increased significantly over the past decades [ 74 ] . …”

Berberine inhibits the production of thymic stromal lymphopoietin by the blockade of caspase-1/NF-κB pathway in mast cells

“…AD, characterized by pruritic and eczematoid skin lesions, affects up to 20% of children and 1-3% of adults in most countries of the world [1,2]. The most common form of AD, accounting for 70-80% of cases, is allergic AD with elevated concentrations of total and allergen-specific immunoglobulin (Ig)E in serum and skin.…”